Back to News
Dec 16, 2025 12:00 PM

Pfizer Sees Slower 2026 Growth Despite Pipeline Push, Cost Cuts

Pfizer Inc. (NYSE:PFE) on Tuesday gave a first glimpse of its fiscal 2026 guidance. The U.S. pharma giant sees 2026 adjusted earnings of $2.80-$3.00 per share compared to the consensus of $3.06.

Pfizer expects sales of $59.5 billion-$62.5 billion versus the Wall Street estimate of $61.65 billion.

Full-year 2026 revenue guidance includes the expectation of revenues from COVID-19 products being approximately $1.5 billion lower than what is expected in 2025, plus an expected year-over-year negative revenue impact of approximately $1.5 billion due to certain products experiencing loss of exclusivity (LOE).

Also Read: Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst

Pfizer expects full-year 2026 operational revenue growth at the midpoint, excluding both COVID-19 and LOE products, to be approximately ...